What's in Chengdu New Radiomedicine Technology Co. LTD.'s pipeline?

Chengdu New Radiomedicine Technology Co. LTD. has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Chengdu New Radiomedicine Technology Co. LTD.'s portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Chinese Society of Lung Cancer, Hutchmed, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chengdu-new-radiomedicine-technology-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Chengdu New Radiomedicine Technology Co. LTD. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chengdu New Radiomedicine Technology Co. LTD. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
NRT6003 Injection	NRT6003 Injection	phase 3			Oncology
cTACE	cTACE	phase 3	chemotherapy		Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 shared drug class
Chinese Society of Lung Cancer · 1 shared drug class
Hutchmed · 1 shared drug class
Pfizer · 1 shared drug class
Prof. Massimo Aglietta · 1 shared drug class
Sanofi · 1 shared drug class
Sun Yat-sen University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Chengdu New Radiomedicine Technology Co. LTD.:

Cite this brief

Drug Landscape (2026). Chengdu New Radiomedicine Technology Co. LTD. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chengdu-new-radiomedicine-technology-co-ltd. Accessed 2026-05-17.